Form 3 - Initial statement of beneficial ownership of securities
2023年9月16日 - 5:45AM
Edgar (US Regulatory)
Exhibit 24.1
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned
hereby constitutes and appoints Dror Bashan, Eyal Rubin and Joseph R. Magnas the undersigned’s true and lawful attorney-in-fact
to: (i) execute for and on behalf of the undersigned, Forms ID, 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange
Act of 1934, as amended and the rules thereunder in connection with the undersigned’s holdings of and transactions in securities
issued by Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”); (ii) do and perform any and all acts for
and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file
such form with the U.S. Securities and Exchange Commission and any required stock exchange or similar authority, including the NYSE American
and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact,
may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed
by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to such attorney-in-fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact’s substitute
or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming,
nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act
of 1934, as amended.
This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and
transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing
attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of September 14, 2023.
/s/ Eliot Richard Forster, Ph.D. |
Name: Eliot Richard Forster, Ph.D. |
Protalix BioTherapeutics (AMEX:PLX)
過去 株価チャート
から 11 2024 まで 12 2024
Protalix BioTherapeutics (AMEX:PLX)
過去 株価チャート
から 12 2023 まで 12 2024